Experimental Alzheimer's drug showing early promise

Ray is two years into his diagnosis.

NBC - An experimental drug for Alzheimer’s disease is showing early promise.

Drug maker Biogen developed the drug called "Aducanumab" and funded this latest research. The drug was found to significantly reduce plaques in the brain, which experts believe play a critical role in the development of Alzheimer’s.

Related: Here's how many people in Tennessee are diagnosed with Alzheimer's disease

Experts are cautious, saying the study was too small to prove any real clinical benefit. Previous drugs have been encouraging in early trials, then later failed.

Still, Dr. Natalie Azar with the NYU Langone Medical Center says this research is promising.

"These plaques can start to surface years, even like a decade before symptoms start. So imagine if you could take a population of people who are at risk, either by screening or genetic risk, and give them this drug that early and prevent the plaques from ever developing,” Dr. Azar said” Could that then translate into a truly meaningful treatment for Alzheimer’s?"

Related: Living with Alzheimer's: Fading memories

Researchers hope to have an answer to that question when the research is finished, likely in the year 2020.


To find out more about Facebook commenting please read the
Conversation Guidelines and FAQs

Leave a Comment